Search Follow us


Orexo’s Q316 results delivered positive momentum in Zubsolv revenues and market share. Exclusive preferred status on Maryland FFS Medicaid from July boosted Zubsolv’s market share in the public segment by 1.4pp. In the coming quarters we expect further US market share gains. Orexo is targeting a disproportionally higher share of new patients embarking on opioid dependence treatment, enabled by continued salesforce optimisation. The impact of the US Department of Health and Human Services’ (HHS) increased 275 patient cap coupled with CARA 2016 implementation from H217 and ongoing progress in improving market access will support this. Nevertheless, the share price performance remains muted ahead of a Q416 court decision on the Actavis IP litigation.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs